Literature DB >> 25483573

Spindle cell metaplastic carcinoma of breast: A clinicopathological and immunohistochemical analysis.

Hong Zhu1, Ke Li1, Dan-Dan Dong1, Jing Fu1, Dan-Dan Liu1, Lei Wang1, Gang Xu1, Lin-Hong Song1.   

Abstract

AIM: To better characterize spindle cell metaplastic carcinoma (SpCMC) of breast, a rare variant of breast cancer that has been classified under the broad rubric of metaplastic carcinoma.
METHODS: We presented herein 19 cases of metaplastic breast carcinoma with dominant spindle cell component. All cases were clinically of breast origin, showed more than 80% spindle morphology, 10 cases exhibited pure spindled morphology, 8 contained invasive ductal carcinoma (IDC) and 1 presented with ductal carcinoma in situ elements.
RESULTS: Immunohistochemical studies showed evidence suggesting myoepithelial and epithelial differentiation as exhibited by immunoreactivity for at least one myoepithelial and epithelial markers in all pure spindle cell components. IDC group showed 21.7% of axillary lymph nodes metastasis rate, whereas the axillary lymph node metastasis rate of the SpCMC group was 1.3%, significantly lower than that of the IDC group (P < 0.001). Immunohistochemical staining of IDC exhibited higher degrees of positivity for ER, PR and Her2 (90, 60 and 30%, respectively) when compared with the SpCMC group, which showed a positive degree of 5.2, 5.2 and 10.5% for ER, PR and Her2, respectively (P < 0.001).
CONCLUSION: Based on this series, SpCMC is a rare variant of metaplastic breast carcinoma with the distinct histopathological and immunohistochemical features. The biological behaviors of SpCMC, like axillary lymph node status, were quite different from that of IDC, suggesting that it may act as an independent pathologic subtype. Immunohistochemical analysis of a panel of epithelial and myoepithelial markers could contribute to the pathologic diagnosis of SpCMC.
© 2014 Wiley Publishing Asia Pty Ltd.

Entities:  

Keywords:  classification; clinicopathology; immunohistochemistry; invasive ductal carcinoma (IDC); spindle cell metaplastic carcinoma of breast (SpCMC)

Mesh:

Substances:

Year:  2014        PMID: 25483573     DOI: 10.1111/ajco.12322

Source DB:  PubMed          Journal:  Asia Pac J Clin Oncol        ISSN: 1743-7555            Impact factor:   2.601


  5 in total

1.  Metaplastic breast carcinoma: a retrospective study of 26 cases.

Authors:  Xuemei Zhou; Xia Wu; Liming Wang; Jiannan Guo; Qiong Wu; Wenqing Song; Yan Zhao; Zhenzhong Feng; Shiwu Wu; Ligong Zhang; Xiaomeng Gong
Journal:  Int J Clin Exp Pathol       Date:  2021-03-01

2.  A 52-Year-Old Woman Presenting With a Right Breast Mass: A Case Report.

Authors:  Robert P Frantz; Mariam Hanna
Journal:  Cureus       Date:  2022-07-23

3.  Metaplastic carcinoma of the breast: Clinicopathological features and treatment outcomes with long-term follow up.

Authors:  Aron Gortman; Noel J Aherne; Justin Westhuyzen; Julan V Amalaseelan; Patrick M Dwyer; Matthew Hoffmann; Andrew T Last; Thomas P Shakespeare
Journal:  Mol Clin Oncol       Date:  2021-07-01

Review 4.  Rare variant of metaplastic carcinoma of the breast: a case report and review of the literature.

Authors:  H Alaoui M'hamdi; F Abbad; H Rais; H Asmouki; A Soumani; M Khouchani; R Belbaraka
Journal:  J Med Case Rep       Date:  2018-02-21

Review 5.  Breast carcinomas of low malignant potential.

Authors:  Stuart J Schnitt; Falko Fend; Thomas Decker
Journal:  Virchows Arch       Date:  2021-07-22       Impact factor: 4.064

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.